If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
The Brighterside of News on MSN1d
First of its kind drug significantly reduces heart attacks and strokesA recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.
Oli Welsh is senior editor, U.K., providing news, analysis, and criticism of film, TV, and games. He has been covering the business & culture of video games for two decades. While it may seem an ...
Medpage Today on MSN6d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney DiseaseThe dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback